Skip to content Skip to footer
Insights+ Key Biosimilars Events of June 2021

Insights+ Key Biosimilars Events of June 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyBiosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patientsDuring the month of Jun, Celltrion launched Remsima SC (biosimilar, infliximab) for…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]